athenahealth price target raised to $140 at Baird after Elliott discloses stakeAfter Elliot Associates disclosed a 9.3% stake in athenahealth, Baird analyst Matthew Gillmor said he is optimistic the activist investor will have a positive influence though he thinks a takeout is less likely. He thinks margin improvement "may be the path of least resistance" and that Elliot's stake highlights athenahealth's unique competitive positioning "at the very least." Gillmor keeps an Outperform rating on athenahealth shares and raised his price target to $140 from $130. |